SEATTLE, WA--(Marketwired - Jan 16, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, today announced that it has entered into an agreement with Diego Pellicer, Inc. and Diego Pellicer Worldwide Inc. which will permit the company use of the Diego Pellicer name for its Phytofare™ cannabis extracts in medical and pharmaceutical marijuana applications.
Diego Pellicer Inc. which was cofounded by the great grandson of Diego Pellicer, the former Vice Governor of the Island of Cebu the Philippines, has created the most recognized brand of cannabis in the world, building on the legacy of Vice Governor Pellicer, who was the largest grower of hemp in the world in the late 1800s, supplying hemp rope to the Spanish Armada during the Spanish American War.
Roger Baylis-Duffield, Chairman and Chief Executive Officer of Plandaí Biotechnology, commented, "Diego Pellicer has been the leading name in cannabis products for over a hundred years and represents everything that Plandaí stands for from a product standpoint; namely, an exhaustive dedication to quality. Being able to sell the Plandaí cannabinoid extracts under the Diego Pellicer name brings immediate name recognition and branding into the medicinal cannabis industry."
The new Diego Pellicer Gold™ cannabinoid extracts provides for efficient recovery of highly bioavailable and active antioxidants from live plant materials in a mainly nano particle form. The cannabinoids, including Δ9-THC (Delta 9-THC) and CBDs are then delivered in a Pheroid®-protected state to the white blood cells without degradation or metabolization.
For medical and recreational applications where the metabolization of THC is preferred, such as in treating chronic pain, the Pheroid® entrapment step will be omitted, resulting in a highly bioavailable cannabinoid extract that will result in significantly lower required dosages. Plandaí anticipates producing both capsules and cannabis oil (for vapor use) in Pheroid™ and non-Pheroid™ versions with the immediate goal of generating nutraceutical sales while pursuing eventual FDA clearance for pharmaceutical applications.
Jamen Shively, co-founder of Diego Pellicer, added, "We couldn't be happier with our partnership with Plandaí. Their Phytofare™ technology appears to be years ahead of the competition as it relates to bioavailability and will help anchor the Diego brand as more states legalize cannabis for medical and/or recreational applications. Plandaí can provide pharmaceutical-grade extracts, with or without psychoactive properties, that will significantly lower costs to the end customer, which is critically important for medical cannabis, as well as provide superior products. In addition, adverse side effects and risks of overconsumption will be greatly mitigated, by providing higher purity, with substantially lower dosage requirements for achieving a desired outcome."
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its patented Phytofare™ extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
The information provided may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Plandaí's ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Plandaí is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.